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ABSTRACT
Objective: In ST elevation myocardial infarction
women received less evidence-based medicine and
had worse outcome during the ﬁbrinolytic era. With the
shift to primary percutaneous coronary intervention
(pPCI) as preferred reperfusion strategy, the authors
aimed to investigate whether these gender differences
has diminished.
Design, setting and participants: Cohort study
including consecutive ST elevation myocardial
infarction patients registered 1998e2000 (n¼15697)
and 2004e2006 (n¼14380) in the Register of
Information and Knowledge about Swedish Heart
Intensive care Admissions.
Outcome measures: 1. Use of evidence-based
medicine such as reperfusion therapy (pPCI or
ﬁbrinolysis) and evidence-based drugs at discharge.
2. Inhospital and 1-year mortality.
Results: Of those who got reperfusion therapy, pPCI
was the choice in 9% in the early period compared
with 68% in the late period. In the early period,
reperfusion therapy was given to 63% of women
versus 71% of men, p<0.001. Corresponding ﬁgures
in the late period were 64% vs 75%, p<0.001. After
multivariable adjustments, the ORs (women vs men)
were 0.86 (95% CI 0.78 to 0.94) in the early and 0.80
(95% CI 0.73 to 0.89) in the late period. As regards
evidence-based secondary preventive drugs at
discharge in hospital survivors (platelet inhibitors,
statins, ACE inhibitors/angiotensin receptor blockers
and b-blockers), there were small gender differences
in the early period. In the late period, women had
14%e25% less chance of receiving these drugs, OR
0.75 (95% CI 0.68 to 0.81) through 0.86 (95% CI 0.73
to 1.00). In both periods, multivariable-adjusted
inhospital mortality was higher in women, OR 1.18
(95% CI 1.02 to 1.36) and 1.21 (1.00 to 1.46). One-
year mortality was gender equal, HR 0.95 (95% CI
0.87 to 1.05) and 0.96 (0.86 to 1.08), after adding
evidence-based medicine to the multivariable
adjustments.
Conclusion: In spite of an intense gender debate,
focus on guideline adherence and the change in
reperfusion strategy, the last decade gender
differences in use of reperfusion therapy and evidence-
based therapy at discharge did not decline during the
study period, rather the opposite. Moreover, higher
mortality in women persisted.
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ARTICLE SUMMARY
Article focus
- With (1) the focus on treatment guidelines, (2)
the attention on gender differences in manage-
ment and outcome and (3) the change in
reperfusion strategy in STEMI in the last
decade, we hypothesised
- that gender differences in adherence to treatment
guidelines would have diminished and
- that gender differences in outcome would have
decreased.
Key messages
- Management improved and mortality decreased
in STEMI patients in the late compared with the
early period.
- The gender treatment gap did not decrease
between the two time periods.
- The gender outcome gap did not decrease
between the two time periods.
Strengths and limitations of this study
- The study included a huge amount of STEMI
patients, with enough numbers to assure
adequate statistical analyses. Swedish Web-
system for Enhancement and Development of
Evidence-based care in Heart disease Evaluated
According to Recommended Therapies register is
a unique Swedish National Quality register, with
quality control and audit measures, covering all
hospitals in Sweden treating STEMI patients and
has standardised criteria for deﬁning MI.
Mortality data are complete as the vital status
of all Swedish citizens is registered in the Cause
of Death Register. One limitation is the non-
randomised observational nature. Thus, multi-
variate analyses were used in order to reduce the
bias inherent in this type of studies. Adjustments
might be inﬂuenced by the lack of registration on
some possible confounding factors in the
database, for example, non-cardiac comorbidities
and contraindications for speciﬁc treatments.
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Open Access ResearchINTRODUCTION
Numerous studies have shown excess mortality in
women after myocardial infarction (MI),
1 2 but ST
elevation myocardial infarction (STEMI) has seldom
been separated from non-ST elevation acute coronary
syndromes.
13Women have been treated less intensively
than men
45with less reperfusion therapy in the STEMI
group.
5 Whereas some have found small gender differ-
ences in treatment not affecting mortality after MI,
3
others have attributed part of the gender gap in
outcome to a treatment bias.
1 Higher risk of death and
bleeding in women is shown in many ﬁbrinolytic trials.
26
In the last decade, there has been a shift in reperfusion
strategy in Sweden from ﬁbrinolytic to primary percuta-
neous coronary intervention (pPCI). Simultaneously,
there has been an increase in use of evidence-based
cardiovascular secondary preventive drugs, such as
statins, P2Y12 inhibitors and ACE inhibitors/angiotensin
receptor blockers (ARBs), and the case fatality has
declined. There is less ﬁrm evidence that female gender
is an independent risk factor for adverse outcome after
pPCI which seems to be a better reperfusion strategy for
women in particular.
7e10 Since 2002/2003, there are
separate ESC guidelines for STEMI and NSTE ACS
recommending pPCI as the preferred reperfusion
strategy in STEMI.
11 12 With the last decade’s awareness
and debate about ACS from a gender perspective, the
focus on adherence to treatment guidelines and the shift
to a reperfusion strategy, we hypothesised that the
previously noticed gender differences in STEMI
management would have decreased and thus also the
gender gap in mortality, especially in the early phase.
Our aim was to evaluate gender differences in
management and outcome in STEMI patients in two
time periods with different dominating reperfusion
strategies, that is, ﬁbrinolytics and pPCI, respectively.
METHODS
Patients
Data for this study came from the prospective observa-
tional Register of Information and Knowledge about
Swedish Heart Intensive care Admissions (RIKS-HIA),
since 2009 merged with the Swedish Coronary Angiog-
raphy and Angioplasty Registry, the Swedish Heart
Surgery Registry and the National Registry of Secondary
Prevention (SEPHIA) together forming the Swedish
Web-system for Enhancement and Development of
Evidence-based care in Heart disease Evaluated
According to Recommended Therapies (SWEDE-
HEART).
13 The RIKS-HIA/SWEDEHEART register is
a large national quality register funded by the National
Board of Health and Welfare (Socialstyrelsen). It
contains information about all patients admitted to
coronary care units (CCU) of the participating hospitals
in Sweden (95% of the CCUs in Sweden year 2004).
Variables including age, sex, smoking habits, comor-
bidity, delay times, symptoms, biochemical markers,
results from cardiac investigations, complications, revas-
cularisation procedures, therapies, discharge diagnoses
and outcomes during the hospital stay are continuously
recorded on-line over the internet. The criteria for the
MI diagnosis were standardised and identical for all
participating hospitals.
14 15 The register has a contin-
uous internal and external validation of data. The
internet-based programme for data input has interactive
instructions, manuals, deﬁnitions and help functions
and a number of compulsory variables and inbuilt
validity controls. An independent monitor travels to 20
hospitals annually and in each hospital 30 randomly
chosen patients in the database are compared with the
hospital records. For example, year 2005, 95.2% and
2006, 96.5% of the registry input showed agreement with
the hospital records.
RIKS-HIA/SWEDEHEART is repeatedly further
merged with the administrative registers National Cause
of Death register and the National Patient Register
(National Board of Health and Welfare is responsible for
both those registers). The Cause of Death Register
covers all Swedish residents, whether the death occurred
in Sweden or not and whether the person in question
was a Swedish citizen or not. From this register, infor-
mation was available about cause of death and vital status
of all Swedish citizens until 31 December 2007.
Regarding comorbidity, data on previous diagnoses of
diabetes, hypertension, MI and previous revascularisa-
tion procedures were taken from RIKS-HIA, Swedish
Coronary Angiography and Angioplasty Registry and the
Swedish Heart Surgery Registry, which were merged
(today SWEDEHEART). Previous history of comorbid-
ities such as chronic obstructive pulmonary disease
(COPD), heart failure, chronic kidney disease, periph-
eral artery disease (PAD), dementia and cancer was
obtained from the National Patient Register, including
patients hospitalised in Sweden since 1987. Information
on previous history of heart failure or stroke was taken
both from RIKS-HIA and the National Patient Register. A
patient was coded as having the diagnosis if he/she had
the diagnosis in either of these registries.
Between 1 January 1995 until 31 December 2006,
54146 patients were admitted to participating CCUs with
the ﬁrst registry recorded diagnosis of STEMI, deﬁned as
ST elevation on admission ECG and a diagnosis of acute
MI at discharge. Patients with pacemaker/unknown/
unspeciﬁed rhythm or bundle branch block on admission
were excluded. Two time periods with different domi-
nating reperfusion strategies were chosen (ﬁgure 1):
patients admitted 1 January 1998 until 31 December 2000
(the early period) and patients admitted 1 January 2004
until 31 December 2006 (the late period). The yearly
STEMI prevalence was similar and about 5000 (women
comprising 33%e36%) ranging from 4662 (year 2006) to
5308 (year 2000). The groups were compared, and
gender comparisons were done in both groups.
Statistical analyses
Continuous variables were summarised by their mean
and SD or median and IQR as appropriate. Categorical
variables were summarised by counts and percentages.
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by c
2 tests for categorical variables and by Student
t tests or ManneWhitney tests for continuous variables.
p Values <0.05 were considered to indicate statistical
signiﬁcance.
Crude, age- and multivariable-adjusted ORs with 95%
CIs were calculated from logistic regression analyses in
order to compare the genders regarding use of cardiac
procedures, evidence-based therapies at discharge and
inhospital mortality. In addition to sex and age, the
multivariable-adjusted analyses included smoking,
previous MI, percutaneous coronary intervention, coro-
nary artery bypass grafting, stroke, hypertension, dia-
betes mellitus, COPD, heart failure, chronic kidney
disease, PAD, dementia, cancer within 3 years, therapies
on arrival, interventional hospital and year of inclusion.
Regarding use of coronary angiography, reperfusion
therapy and inhospital mortality, we also added Killip
class on arrival and symptom-to-door time (as a contin-
uous variable in 1-h intervals) to the multivariable-
adjusted analyses. Data from the logistic regression
analyses are shown in forest plots.
HRs with 95% CIs were calculated from Cox propor-
tional hazard regression analyses in order to compare
the genders regarding cumulative 1-year mortality. The
ﬁrst multivariable-adjusted analysis included the same
variables as ﬁrst described above. In a second multivari-
able-adjusted analysis, we also added reperfusion therapy
and evidence-based therapies at discharge (platelet
inhibitors, b-blockers, ACE inhibitors/ARBs and statins).
Data from the Cox regression analyses are shown in
forest plots.
Missing values for all variables were controlled (1%e
2%). As symptom-to-door time was available for 82% of
the patients, a sensitivity analysis was done. Logistic
regression analyses regarding use of coronary angiog-
raphy, reperfusion therapy and inhospital mortality were
done also without incorporating symptom-to-door time.
These analyses did not substantially change the results
(supplementary table).
All statistical analyses were performed with the SPSS
(PASW Statistics) V.18.0 software (SPSS, Inc).
Ethical considerations
The register was approved by the National Board of
Health and Welfare, and the process of merging the
RIKS-HIA register with other registries was approved by
the Swedish Data Inspection Board. The study was
approved by the ethical committee and complies with
the Declaration of Helsinki.
RESULTS
Baseline characteristics
A total of 30077 STEMI patients were admitted during
the two inclusion periods, 15697 (35% women) in
1998e2000 and 14380 (35% women) in 2004e2006.
The mean age did not differ between the two periods,
whereas the prevalence of previous MI was lower, and the
prevalence of COPD and smoking was higher in the late
period. In both time periods, women were 6.5 years
older than men and had more often diabetes, hyper-
tension, heart failure, COPD, or previous stroke, whereas
men were more often smokers and were previously
revascularised (table 1).
The use of statins, clopidogrel and ACE inhibitors/
ARB on admission increased between the two time
periods. Women were more frequently treated with
diuretics, digitalis, calcium channel blocker and long-
acting nitrates on admission in both time periods.
Women had 30 min longer median symptom-to-door
time in both time periods. Also the median time from
ﬁrst ECG to needle differed between the genders in both
time periods (4 and 5 min, respectively), whereas the
median time from ﬁrst ECG to balloon only differed in
the late time period (5 min) (table 1).
Hospital care
In the early period, coronary angiography was
performed in fewer women than men (18% vs 25%). In
the late period, the numbers were higher in both
genders (66% vs 82%) (table 1). After multivariable
adjustments, women had 8% vs 20% less chance of
angiography in early and late periods, respectively (OR
0.92, 95% CI 0.83 to 1.02 vs OR 0.80, 95% CI 0.71 to
0.90) (supplementary table). Among patients treated
with reperfusion therapy, 9% (7% of women, 10% of
men, table 1) were treated with pPCI in the early
compared with 68% (64% of women, 69% of men, table
1) in the late period. Sixty-three per cent of women
compared with 71% of men received acute reperfusion
therapy in the early compared with 64% and 75% in the
late period (table 1). After multivariable adjustment,
women were 14% and 20% less likely to receive reper-
fusion therapy in the early and late periods, respectively,
compared with men (OR 0.86, 95% CI 0.78 to 0.94 vs OR
0.80, 95% CI 0.73 to 0.89) (ﬁgure 2, supplementary
table). Patients in the early period had more often heart
failure and lower Killip class but less major bleedings. In
both early and late periods, women had more often
heart failure and bleeding complications during hospital
stay (table 1).
Figure 1 Trends in reperfusion therapy among Swedish
STEMI patients from 1995 to 2006. pPCI, primary
percutaneous coronary intervention.
Lawesson SS, Alfredsson J, Fredrikson M, et al. BMJ Open 2012;2:e000726. doi:10.1136/bmjopen-2011-000726 3
Time trends in STEMI management and outcome from a gender perspectiveT
a
b
l
e
1
B
a
s
e
l
i
n
e
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
,
m
a
n
a
g
e
m
e
n
t
a
n
d
o
u
t
c
o
m
e
E
a
r
l
y
p
e
r
i
o
d
:
y
e
a
r
1
9
9
8
e
2
0
0
0
L
a
t
e
p
e
r
i
o
d
:
y
e
a
r
2
0
0
4
e
2
0
0
6
P
e
r
i
o
d
s
c
o
m
p
a
r
e
d
M
e
n
(
n
[
1
0
1
5
1
)
W
o
m
e
n
(
n
[
5
5
4
6
)
p
V
a
l
u
e
M
e
n
(
n
[
9
3
8
6
)
W
o
m
e
n
(
n
[
4
9
9
4
)
p
V
a
l
u
e
p
V
a
l
u
e
A
g
e
,
i
n
y
e
a
r
s
(
S
D
s
)
6
6
.
4
(
1
2
.
2
)
7
2
.
9
(
1
1
.
5
)
<
0
.
0
0
1
6
5
.
9
(
1
2
.
2
)
7
2
.
4
(
1
2
.
1
)
<
0
.
0
0
1
0
.
1
1
M
e
d
i
a
n
s
y
m
p
t
o
m
-
t
o
-
d
o
o
r
t
i
m
e
,
h
:
m
(
I
Q
R
)
2
:
4
5
(
1
:
3
9
e
5
:
1
0
)
3
:
1
5
(
1
:
5
4
e
6
:
1
5
)
<
0
.
0
0
1
3
:
0
0
(
1
:
4
0
e
5
:
5
0
)
3
:
3
0
(
2
:
0
0
e
6
:
3
0
)
<
0
.
0
0
1
<
0
.
0
0
1
y
M
e
d
i
a
n
t
i
m
e
f
r
o
m
ﬁ
r
s
t
E
C
G
t
o
b
a
l
l
o
o
n
,
h
:
m
(
I
Q
R
)
1
:
0
0
(
0
:
3
5
e
1
:
3
9
)
0
:
5
8
(
0
:
3
5
e
1
:
4
2
)
0
.
6
0
1
:
1
0
(
0
:
4
2
e
1
:
4
9
)
1
:
1
5
(
0
:
4
5
e
1
:
5
9
)
<
0
.
0
0
1
<
0
.
0
0
1
y
M
e
d
i
a
n
t
i
m
e
f
r
o
m
ﬁ
r
s
t
E
C
G
t
o
n
e
e
d
l
e
,
h
:
m
(
I
Q
R
)
0
:
4
3
(
0
:
2
7
e
1
:
0
5
)
0
:
4
7
(
0
:
3
0
e
1
:
1
5
)
<
0
.
0
0
1
0
:
3
6
(
0
:
2
0
e
1
:
0
2
)
0
:
4
1
(
0
:
2
3
e
1
:
0
8
)
0
.
0
0
1
<
0
.
0
0
1
z
C
o
m
o
r
b
i
d
i
t
y
C
u
r
r
e
n
t
s
m
o
k
e
r
2
7
6
2
(
2
8
.
9
)
1
2
2
0
(
2
3
.
8
)
<
0
.
0
0
1
2
6
8
0
(
3
0
.
9
)
1
2
2
4
(
2
7
.
6
)
<
0
.
0
0
1
<
0
.
0
0
1
y
P
r
e
v
i
o
u
s
m
y
o
c
a
r
d
i
a
l
i
n
f
a
r
c
t
i
o
n
1
7
8
1
(
1
7
.
5
)
7
4
2
(
1
3
.
4
)
<
0
.
0
0
1
1
0
6
2
(
1
1
.
3
)
5
2
9
(
1
0
.
6
)
0
.
1
9
<
0
.
0
0
1
z
P
r
e
v
i
o
u
s
P
C
I
2
8
7
(
2
.
9
)
8
7
(
1
.
6
)
<
0
.
0
0
1
3
7
2
(
4
.
0
)
1
1
0
(
2
.
2
)
<
0
.
0
0
1
<
0
.
0
0
1
y
P
r
e
v
i
o
u
s
c
o
r
o
n
a
r
y
a
r
t
e
r
y
b
y
p
a
s
s
g
r
a
f
t
i
n
g
3
0
7
(
3
.
1
)
5
8
(
1
.
1
)
<
0
.
0
0
1
3
0
8
(
3
.
3
)
8
2
(
1
.
7
)
<
0
.
0
0
1
0
.
0
5
y
D
i
a
b
e
t
e
s
m
e
l
l
i
t
u
s
1
7
5
8
(
1
7
.
3
)
1
1
9
8
(
2
1
.
6
)
<
0
.
0
0
1
1
6
7
9
(
1
7
.
9
)
1
0
1
4
(
2
0
.
3
)
<
0
.
0
0
1
0
.
8
2
H
y
p
e
r
t
e
n
s
i
o
n
2
7
3
6
(
2
7
.
2
)
1
9
7
2
(
3
6
.
0
)
<
0
.
0
0
1
3
0
5
3
(
3
2
.
8
)
2
1
9
5
(
4
4
.
5
)
<
0
.
0
0
1
<
0
.
0
0
1
y
C
o
n
g
e
s
t
i
v
e
h
e
a
r
t
f
a
i
l
u
r
e
5
8
6
(
5
.
8
)
5
1
8
(
9
.
3
)
<
0
.
0
0
1
4
0
6
(
4
.
3
)
4
5
5
(
9
.
1
)
<
0
.
0
0
1
<
0
.
0
0
1
z
P
r
e
v
i
o
u
s
s
t
r
o
k
e
7
6
9
(
7
.
6
)
5
0
9
(
9
.
2
)
<
0
.
0
0
1
7
8
0
(
8
.
3
)
5
2
3
(
1
0
.
5
)
<
0
.
0
0
1
0
.
0
4
y
C
h
r
o
n
i
c
k
i
d
n
e
y
d
i
s
e
a
s
e
8
9
(
0
.
9
)
4
0
(
0
.
7
)
0
.
3
0
1
1
3
(
1
.
2
)
7
2
(
1
.
4
)
<
0
.
0
0
1
<
0
.
0
0
1
y
C
h
r
o
n
i
c
o
b
s
t
r
u
c
t
i
v
e
p
u
l
m
o
n
a
r
y
d
i
s
e
a
s
e
4
4
8
(
4
.
4
)
3
5
8
(
6
.
5
)
<
0
.
0
0
1
4
6
5
(
5
.
0
)
4
4
0
(
8
.
8
)
<
0
.
0
0
1
<
0
.
0
0
1
y
C
a
n
c
e
r
w
i
t
h
i
n
3
y
e
a
r
s
2
4
6
(
2
.
4
)
1
6
0
(
2
.
9
)
0
.
0
8
2
7
7
(
3
.
0
)
1
4
9
(
3
.
0
)
0
.
9
1
0
.
0
5
y
T
h
e
r
a
p
y
o
n
a
r
r
i
v
a
l
A
s
p
i
r
i
n
2
6
8
0
(
2
6
.
6
)
1
5
1
2
(
2
7
.
5
)
0
.
2
5
2
1
2
7
(
2
2
.
9
)
1
4
4
0
(
2
9
.
2
)
<
0
.
0
0
1
<
0
.
0
0
1
z
O
t
h
e
r
p
l
a
t
e
l
e
t
i
n
h
i
b
i
t
o
r
3
7
(
0
.
4
)
1
6
(
0
.
3
)
0
.
4
3
3
0
9
(
3
.
3
)
1
9
5
(
3
.
9
)
0
.
0
5
<
0
.
0
0
1
y
B
e
t
a
-
b
l
o
c
k
e
r
2
5
2
5
(
2
5
.
1
)
1
5
4
4
(
2
8
.
1
)
<
0
.
0
0
1
2
1
9
4
(
2
3
.
6
)
1
5
6
5
(
3
1
.
8
)
<
0
.
0
0
1
0
.
5
7
A
C
E
i
n
h
i
b
i
t
o
r
/
A
R
B
1
0
8
1
(
1
0
.
7
)
5
8
6
(
1
0
.
7
)
0
.
8
9
1
5
5
3
(
1
6
.
7
)
9
2
4
(
1
8
.
7
)
0
.
0
0
2
<
0
.
0
0
1
y
S
t
a
t
i
n
7
5
0
(
7
.
5
)
3
1
8
(
5
.
8
)
<
0
.
0
0
1
1
2
4
9
(
1
3
.
4
)
6
2
1
(
1
2
.
6
)
0
.
1
6
<
0
.
0
0
1
y
O
r
a
l
a
n
t
i
c
o
a
g
u
l
a
n
t
2
7
1
(
2
.
7
)
1
0
9
(
2
.
0
)
0
.
0
0
6
2
3
2
(
2
.
5
)
1
1
9
(
2
.
4
)
0
.
7
6
0
.
9
1
C
a
l
c
i
u
m
c
h
a
n
n
e
l
b
l
o
c
k
e
r
1
3
0
4
(
1
3
.
0
)
7
8
6
(
1
4
.
3
)
0
.
0
2
1
0
7
5
(
1
1
.
6
)
7
2
2
(
1
4
.
6
)
<
0
.
0
0
1
0
.
0
4
z
D
i
u
r
e
t
i
c
s
1
4
5
3
(
1
4
.
4
)
1
5
2
0
(
2
7
.
7
)
<
0
.
0
0
1
1
1
8
2
(
1
2
.
7
)
1
4
0
7
(
2
8
.
5
)
<
0
.
0
0
1
0
.
0
4
z
D
i
g
i
t
a
l
i
s
3
8
8
(
3
.
9
)
3
4
3
(
6
.
3
)
<
0
.
0
0
1
1
5
6
(
1
.
7
)
2
1
4
(
4
.
3
)
<
0
.
0
0
1
<
0
.
0
0
1
z
L
o
n
g
-
a
c
t
i
n
g
n
i
t
r
a
t
e
s
1
0
5
3
(
1
0
.
5
)
6
7
9
(
1
2
.
4
)
<
0
.
0
0
1
4
8
7
(
5
.
2
)
4
3
5
(
8
.
8
)
<
0
.
0
0
1
<
0
.
0
0
1
z
C
C
U
p
r
o
c
e
d
u
r
e
s
a
n
d
t
h
e
r
a
p
i
e
s
E
c
h
o
c
a
r
d
i
o
g
r
a
p
h
y
6
2
0
0
(
6
4
.
2
)
2
9
7
0
(
5
7
.
8
)
<
0
.
0
0
1
6
8
4
2
(
7
3
.
7
)
3
2
8
2
(
6
6
.
5
)
<
0
.
0
0
1
<
0
.
0
0
1
y
C
o
r
o
n
a
r
y
a
n
g
i
o
g
r
a
p
h
y
2
5
3
9
(
2
5
.
0
)
9
7
5
(
1
7
.
6
)
<
0
.
0
0
1
7
6
8
6
(
8
1
.
9
)
3
3
1
6
(
6
6
.
4
)
<
0
.
0
0
1
<
0
.
0
0
1
y
R
e
p
e
r
f
u
s
i
o
n
t
h
e
r
a
p
y
,
a
l
l
7
1
9
4
(
7
0
.
9
)
3
5
0
0
(
6
3
.
1
)
<
0
.
0
0
1
7
0
6
5
(
7
5
.
3
)
3
1
7
4
(
6
3
.
6
)
<
0
.
0
0
1
<
0
.
0
0
1
y
F
i
b
r
i
n
o
l
y
s
i
s
(
%
o
f
a
l
l
p
a
t
i
e
n
t
s
)
6
4
1
9
(
6
3
.
3
)
3
2
2
3
(
5
8
.
2
)
<
0
.
0
0
1
1
9
4
4
(
2
1
.
0
)
1
0
0
6
(
2
0
.
4
)
0
.
4
4
<
0
.
0
0
1
z
F
i
b
r
i
n
o
l
y
s
i
s
(
%
o
f
p
a
t
i
e
n
t
s
r
e
c
e
i
v
i
n
g
r
e
p
e
r
f
u
s
i
o
n
t
h
e
r
a
p
y
)
6
4
1
9
(
8
9
.
3
)
3
2
2
3
(
9
2
.
2
)
<
0
.
0
0
1
1
9
4
4
(
2
8
.
0
)
1
0
0
6
(
3
2
.
4
)
<
0
.
0
0
1
<
0
.
0
0
1
z
P
r
i
m
a
r
y
P
C
I
(
%
o
f
a
l
l
p
a
t
i
e
n
t
s
)
7
1
3
(
7
.
0
)
2
4
8
(
4
.
5
)
<
0
.
0
0
1
4
8
9
8
(
5
2
.
2
)
2
0
3
3
(
4
0
.
7
)
<
0
.
0
0
1
<
0
.
0
0
1
y
P
r
i
m
a
r
y
P
C
I
(
%
o
f
p
a
t
i
e
n
t
s
r
e
c
e
i
v
i
n
g
r
e
p
e
r
f
u
s
i
o
n
t
h
e
r
a
p
y
)
7
1
3
(
9
.
9
)
2
4
8
(
7
.
1
)
<
0
.
0
0
1
4
8
9
8
(
6
9
.
3
)
2
0
3
3
(
6
4
.
1
)
<
0
.
0
0
1
<
0
.
0
0
1
y
C
o
n
t
i
n
u
e
d
4 Lawesson SS, Alfredsson J, Fredrikson M, et al. BMJ Open 2012;2:e000726. doi:10.1136/bmjopen-2011-000726
Time trends in STEMI management and outcome from a gender perspectiveTherapy at discharge
Evidence-based treatment with statins, platelet inhibi-
tors, b-blockers and ACE inhibitors or ARBs were
prescribed more often in the late compared with the
early period in both genders. All evidence-based thera-
pies were prescribed more seldom to women in both
periods (table 1). Women still had less chance of
receiving ACE inhibitors/ARBs but higher chance of
receiving statins after multivariable adjustments in the
early period. In the late period, women had 14%e25%
less chance of receiving any of these therapies after
multivariable adjustments, OR 0.75 (95% CI 0.68 to
0.81) through OR 0.86 (95% CI 0.73 to 1.00) (ﬁgure 2,
supplementary table).
Mortality
Inhospital as well as cumulative 1-year mortality was
higher in the early than in the late period in both
genders. Women had about twice as high inhospital as
well as 1-year mortality in both periods (table 1). After
multivariable adjustments, the inhospital mortality was
around 20% higher in women in both periods (OR 1.18,
95% CI 1.02 to 1.36 vs OR 1.21, 95% CI 1.00 to 1.46).
The 1-year mortality was 5% and 11% higher in women
in the early and late periods, respectively, although it did
not reach statistical signiﬁcance in the early period (HR
1.05, 95% CI 0.97 to 1.14 vs HR 1.11, 95% CI 1.00 to
1.24). After adding adjustment for reperfusion therapy
and evidence-based treatment at discharge, there was no
longer any gender difference in long-term mortality (HR
0.95, 5% CI 0.87 to 1.05 vs HR 0.96, 95% CI 0.86 to 1.08)
(ﬁgure 3, supplementary table).
DISCUSSION
After the reperfusion strategy change, patients admitted
during the ﬁrst decade of the 21st century were treated
with reperfusion therapy more often than patients
admitted during the late 1990s. Anyhow, we did not ﬁnd
a diminished gender gap neither regarding use of
reperfusion therapy nor regarding mortality. Even more
surprising was the ﬁnding that women had 14%e25%
less chance of receiving evidence-based cardio-
vascular treatment in the late period after multivariable
adjustments.
Previous trials during the ﬁbrinolytic era have found
higher mortality in women but usually without sepa-
rating STEMI from NSTE ACS.
1 In STEMI studies, the
risk of early death has been 10%e25% higher in women
after multivariable adjustments
2561 6although most
STEMI cohorts have been extracted from randomised
controlled trials
26and may not correspond to the real-
life population. Fibrinolytics has been given to fewer
women even if eligibility has been considered.
17 Also in
our study, women had 14% lower chance of receiving
reperfusion therapy in the early group where ﬁbrino-
lytics accounted for 91% of the reperfusion therapy. As
an increased risk of intracranial haemorrhage and other
major bleedings has been found in women treated with
ﬁbrinolytics,
18 a fear of these dreadful complications
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Time trends in STEMI management and outcome from a gender perspectivemay explain some of the observed difference. The well-
known longer delay times in women could be another
explanation. In our study, women had 30 min longer
delay times from symptom onset to arrival to CCU or the
cath lab in both time periods. Adjusting for this did not
change the results.
As pPCI has been shown superior to ﬁbrinolytics in
reducing mortality after STEMI,
19 it has been recom-
mended in the ESC guidelines since 2003.
20 In Sweden,
it has been the dominant reperfusion strategy from
2004 and onwards (ﬁgure 1). During this new pPCI
era, the evidence that gender per se bears prognostic
information is less ﬁrm and data are contrasting.
10 21
When we started our study and formed our hypothesis,
there were only small and mainly single-centre studies
published.
781 02 1The majority of those did not ﬁnd
female gender to be an independent predictor of
adverse outcome after pPCI.
71 0Mehilli et al
22 found
better myocardial salvage in women than in men after
pPCI which they speculated could be due to a higher
hypoxia tolerance in women because of higher inci-
dence of preinfarction angina (ischaemic pre-condi-
tioning) and more often spontaneous thrombolysis.
Also, as pPCI is less time dependent than ﬁbrinolytics,
Figure 2 Use of coronary angiography, reperfusion therapy and evidence-based therapies at discharge in STEMI patients in two
time periods after multivariable adjustments, women versus men.
Figure 3 Inhospital and cumulative 1-year mortality in STEMI patients in two time periods with different dominating reperfusion
strategies. Crude, age-adjusted and multivariable-adjusted odds and HRs with 95% CIs, women versus men.
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Time trends in STEMI management and outcome from a gender perspectivewomen could be expected to beneﬁt more than men
from a reperfusion strategy change because of their
consistently longer symptom-to-door time.
10
Thus, our hypothesis was that the gender gap in
reperfusion therapy would diminish after the shift to
a reperfusion strategy that could be more advantageous
to women. This hypothesis was not conﬁrmed. The rate
of reperfusion in men increased from 70.9% to 75.3%,
whereas the increase in women was very modest, 63.1%e
63.6%. The reason for the ﬁnding is for us unclear. The
gender difference in mean age was the same in the two
periods and women had 30 min longer symptom-to-door
time in both periods. One possible reason could be
higher prevalence of normal coronary arteries in
women, which is shown before although mainly in non-
ST elevation acute coronary syndromes and mixed ACS
populations.
23 In our study, during the early period, we
had coronary angiography ﬁndings from few patients
(56% of the 3514 patients that underwent coronary
angiography). In the late period, we had ﬁndings on
97% of the 11002 examined patients showing that 3% of
men and 7% of women had non-obstructive coronary
artery disease. Thus, normal coronary arteries can hardly
explain the gap in reperfusion therapy in the early
period when ﬁbrinolytics was dominating and angiog-
raphy seldom performed. In the late period, it could
account for a small part of the difference in use of pPCI
although it does not explain the gender gap in use of
coronary angiography, which also increased between the
two time periods.
During the last decade, several important randomised
controlled trials have been published encouraging more
effective secondary prevention in CAD patients.
24 25 Use
of ACE inhibitors/ARBs, dual platelet inhibition and
statins has thus increased dramatically in the STEMI
population during this decade and mortality has
declined. We found increased use of all secondary
prevention drugs, even those with older evidence such as
aspirin and b-blockers. However, the increase of all the
evidence-based therapies was more pronounced in men
than in women. In spite of the intense focus on the
gender aspect in the ACS ﬁeld during the last 2 decades,
together with the focus on adherence to guidelines, the
treatment gap was even more pronounced in the late
compared with the early group. Even after multivariable
adjustment, women had 14%e25% lesser chance of
receiving any of these drugs at discharge.
We cannot fully explain this gender gap in manage-
ment. Maybe a fear of doing harm because of the well-
known higher risk of bleeding in women
26 or reports
from patients of previous or current adverse effects are
reasons for the bias. It has been shown in previous
studies that women report side effects more often than
men, especially if the same dosages are used.
27 Finally,
we could speculate that doctors tend to adapt to new
treatment modalities and new guidelines faster in men
than in women, especially in older cohorts. We did some
subgroup analyses of different age groups (not included
in the manuscript) where we found the treatment bias
clearest in the oldest cohort.
A more effective reperfusion strategy with pPCI and
the increased use of evidence-based treatment have been
associated with improved outcome. Thus, we found
reduced mortality in the late compared with the early
period in both genders. However, we also found
a persistent gender gap both regarding short- and long-
term mortality. Inhospital mortality was approximately
20% higher in both time periods consistent with
previous STEMI studies focusing on gender from the
ﬁbrinolytic era.
2 561 6From the percutaneous coronary
intervention era, two recent publications by Benamer
et al and Sadowski et al found that there is still a gender
difference in inhospital mortality among STEMI patients
consistent with our ﬁndings.
28 29 In addition, 1-year
mortality was higher in our study, 5% vs 11% higher in
the early and late periods, respectively. If we also incor-
porated evidence-based treatment at discharge and
reperfusion therapy in the multivariable adjustments,
there was no longer a signiﬁcant gender difference in
long-term mortality.
In the USA, the American College of Cardiology’s AMI
Guidelines Applied in Practice program is proven to
increase the use of evidenced-based medicine and reduce
MI mortality but is less used in women.
30 The results in
our study are in concordance with those ﬁndings.
Limitations
As in all registries on clinical practice, one limitation is
the handling of missing data. In the RIKS-HIA register,
we have data for around 95% of the patients for almost
all variables that is mandatory for the hospitals to
register. Furthermore, as in all observational data sets,
the adjustment might be inﬂuenced by the lack of
registration on some possible confounding factors in the
data base, for example non-cardiac comorbidities,
reduced kidney function and contraindications for
speciﬁc treatments. Accordingly, eligibility for all treat-
ments was not possible to ascertain and might thus differ
between the genders. However, a strength is the large
number of patients allowing adjustment for baseline
differences between the compared groups.
CONCLUSIONS
Our study showed improved management and reduced
mortality in STEMI patients in the late compared with
the early period. Anyhow the gender difference did not
diminish between the two time periods neither
regarding management nor regarding early mortality.
Adherence to treatment guidelines was better in men
than in women, and in fact, the treatment gap seemed
even more pronounced in the new era. There was also
a persistent 20% higher risk of early mortality in women
in the new pPCI era, in accordance with the ﬁbrinolytic
era. Thus, a better adherence to treatment guidelines in
women is mandatory as it might reduce the differences
in outcome between the genders. There is also a great
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Time trends in STEMI management and outcome from a gender perspectiveneed of studies scrutinising the gender differences in
management of STEMI in the new pPCI era.
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